Division of Cardiac Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Division of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
J Card Surg. 2021 Nov;36(11):4030-4037. doi: 10.1111/jocs.15908. Epub 2021 Aug 11.
This study evaluated the utilization and outcomes of postcardiotomy mechanical circulatory support (MCS).
This was a retrospective, single institution analysis of adult cardiac surgery cases that required de novo MCS following surgery from 2011 to 2018. Patients that were bridged with MCS to surgery were excluded. The primary outcomes were early operative mortality and longitudinal survival. Secondary outcomes included postoperative complications, and 5-year all-cause readmission.
Five hundred and thirty-three patients required de novo postcardiotomy MCS, with the most commonly performed procedure being isolated coronary artery bypass grafting (29.8%). Median cardiopulmonary bypass and cross-clamp times were 185 (IQR 123-260) min and 122 (IQR 81-179) min, respectively. A total of 442 (82.9%) of patients were supported with intra-aortic balloon pump counterpulsation, 23 (4.3%) with an Impella device, and 115 (21.6%) with extracorporeal membrane oxygenation. Three (0.6%) patients had an unplanned ventricular assist device placed. Operative mortality was 29.8%. Longitudinal survival was 56.1% and 43.0% at 1 and 5 years, respectively. Survival was lowest in those supported with ECMO and highest with those supported with an Impella (p < 0.001). Freedom from readmission was 61.4% at 5 years. Postoperative ECMO was an independent predictor of mortality (HR 5.1, 95% CI 2.0-12.9, p < 0.001), but none of the MCS types predicted long-term hospital readmission after risk adjustment.
Postcardiotomy MCS is associated with high operative mortality. Even patients that survive to discharge have compromised longitudinal survival, with nearly only half surviving to 1 year. Close follow-up and early referral to advanced heart failure specialists may be prudent in improving these outcomes.
本研究评估了心脏手术后使用机械循环支持(MCS)的情况和结果。
这是一项回顾性、单中心分析,纳入了 2011 年至 2018 年期间因心脏手术后需要新置入 MCS 的成年心脏手术患者。术中接受 MCS 桥接治疗的患者被排除在外。主要结局是早期手术死亡率和纵向生存率。次要结局包括术后并发症和 5 年全因再入院率。
533 例患者需要新置入心脏手术后 MCS,最常进行的手术是单纯冠状动脉旁路移植术(29.8%)。体外循环和主动脉阻断时间中位数分别为 185(IQR 123-260)min 和 122(IQR 81-179)min。442 例(82.9%)患者接受主动脉内球囊反搏支持,23 例(4.3%)接受 Impella 装置支持,115 例(21.6%)接受体外膜肺氧合支持。3 例(0.6%)患者需要临时置入心室辅助装置。手术死亡率为 29.8%。纵向生存率分别为 56.1%和 43.0%,1 年和 5 年时。使用 ECMO 支持的患者生存率最低,使用 Impella 支持的患者生存率最高(p<0.001)。5 年时无再入院率为 61.4%。术后 ECMO 是死亡率的独立预测因素(HR 5.1,95%CI 2.0-12.9,p<0.001),但在风险调整后,没有一种 MCS 类型可以预测长期住院再入院率。
心脏手术后的 MCS 与高手术死亡率相关。即使存活至出院的患者,其纵向生存率也受到影响,近一半的患者在 1 年内死亡。密切随访并尽早转介至先进的心衰专科医生处可能有助于改善这些结局。